SUMMARY In a double-blind double-placebo crossover study naproxen (500-750 mg daily) was found to be equivalent to phenylbutazone (400-600 mg daily) in the control of disease activity in 20 patients suffering from ankylosing spondylitis during a two times 5-week trial period. No serious side effects were observed during the trial period. Gastric complaints occurred twice as often under phenylbutazone as under naproxen. Naproxen has been claimed to be a potent analgesic and anti-inflammatory drug with a relatively low incidence of side effects (Roszkowski et al., 1971; Hill et al., 1974; Huskisson et al., 1976) . A few preliminary studies have shown a beneficial effect in ankylosing spondylitis (Hill and Hill, 1975; Peter and Veress, 1975) . To our knowledge, naproxen has not been compared with phenylbutazone, which is considered the main therapy in this disease. We therefore undertook a double-blind double-placebo crossover study to assess the efficacy and safety of naproxen against phenylbutazone in active ankylosing spondylitis.
Patients with one of the following criteria were excluded: (1) women of child-bearing age; (2) patients with secondary ankylosing spondylitis, such as Behcet's or Reiter's disease; (3) total immobility of the spine and of the costovertebral joints; (4) patients on anticoagulants, hypoglycaemic agents, sulphonamides or other drugs highly bound to plasma proteins; (5) a history of definite peptic ulcer or gastrointestinal bleeding (within the previous 2 years), or ulcerative colitis or regional enteritis at any time; or any significant gastrointestinal disease likely to interfere with drug absorption; (6) a history of hypersensitivity to phenylbutazone or to other nonsteroidal anti-inflammatory drugs, (7) a history of hepatic disease or liver function tests 25 % or more above the normal laboratory values and a history of renal disease shown by blood urea nitrogen (BUN) and creatinine 30% above normal values; (8) those with conditions such as cerebral vascular accident, existing cardiac failure, coronary occlusion within the previous 6 months, active tuberculosis, metabolic bone disease, haematopoietic disorder, malignant disease, depression, or other mental disorders, likely to interfere with the course of or assessment of disease progress.
Patients were assigned randomly to either of two sequences. In sequence A patients were given for the first 5 weeks two tablets of naproxen 250 mg each daily plus 4 placebo tablets mimicking phenylbutazone; for the following 5 weeks they were given twice daily 2 tablets phenylbutazone of 100 mg each plus one placebo tablet identical to the naproxen tablets taken previously. Sequence B was similar but during the first 5-week period the patients took phenylbutazone as the active drug and naproxen was taken in the second 5-week period. No 'washout' period was included either before the trial or at 85 the time of crossover. Patients were switched immediately from their previous drug therapy to both trial medications.
The patients were interviewed and examined at the start of the trial and weekly thereafter. At each visit their evaluation of spinal pain (cervical, thoracic, and lumbar/sacroiliac) and night pain, using a scale from 0 to 4, was recorded as well as duration of morning stiffness and of immobility stiffness (Hill and Hill, 1975) 
Results
Of the 22 patients entered in the study, one dropped out during the first period because of epigastric intolerance. All other patients completed both phases of the study, but to equalise the two groups, the data of one other patient were disregarded in the results. The two groups of 10 patients were comparable for sex, age, weight, height, functional class, duration of disease, and response to previous treatment (Table 1 ). In both groups 3 patients had been receiving indomethacin and 7 phenylbutazone during the 6 months immediately preceding the trial. There were no significant differences in the dosage of both drugs.
During the trial most of the patients experienced less pain and stiffness, although they had been on 'full' treatment up to that time. However, no significant differences were found between the two drugs with regard to the patient's evaluation of spinal pain, nocturnal pain, morning stiffness, immobility stiffness, and onset of fatigue ( Table 2) . The proportion of patients with nocturnal pain was equal after naproxen and phenylbutazone.
The overall response to naproxen and phenylbutazone was assessed as equivalent (at the 5% level) by the patients. In 9 the dosage was increased because of increasing complaints of pain and/or stiffness, three times during the first period and six times during the second period. 4 patients were on phenylbutazone and 5 on naproxen when increased dosage was necessary to continue the trial. (Table 5 ). Only one patient had to be withdrawn from the study because of gastric complaints during phenylbutazone treatment. Ophthalmological investigation, including slit lamp examination, at the end of both trial periods was normal.
Discussion
For this short-term trial the double-blind doubleplacebo crossover design was chosen to assess the value of naproxen in the treatment of ankylosing spondylitis and to compare it with phenylbutazone. The crossover method-with all patients being given each drug in turn-allows the use of a relatively small number of patients. The double-placebo technique reduced the risks of either the investigator or the patients guessing which active drug was being taken and therefore assured as much as possible the maintenance of the double-blindness of the study. Judging from the rheumatology textbooks there seems to be general agreement that phenylbutazone is the most effective drug in the control of the symptoms of ankylosing spondylitis, although its application is hampered by the risks of severe side effects. The results from our study indicate that the effects of naproxen are equivalent to phenylbutazone, based on both the patient's and the physician's evaluation. Little or no differences were found between the values obtained after the trial periods compared to the baseline values, probably because there was no 'wash-out' period before the trial. In earlier studies about 25 % of patients with active ankylosing spondylitis were unable to complete a period of 5 days without a major anti-inflammatory drug. Because the mean half-life of naproxen in man is 13 hours (Segre, 1975) and phenylbutazone 48 to 72 hours (von Rechenberg, 1962) , the length of the trial periods, i.e. 35 days each, was thought sufficient to eliminate completely the possible carry-over effects of preceding treatment.
In contrast with phenylbutazone, few serious side effects of naproxen have been reported. In our study it caused fewer gastric complaints than phenylbutazone. Otherwise, no significant differences between the two drugs with regard to clinical tolerance were found. No consistent abnormal findings were observed among the laboratory parameters, except for transient increase of BUN values occurring with both drugs and in the absence of any other sign of kidney impairment.
Therefore, naproxen seems to be a useful alternative drug to phenylbutazone in the treatment of ankylosing spondylitis, at least on a short-term basis. Recently it has been claimed that long-term treatment with phenylbutazone might delay the ossification of the lumbar discs in ankylosing spondylitis (Boersma, 1976) . A long-term comparative study of naproxen and phenylbutazone seems to be wanting. 
